ArticleFrontiers in nutrition2022
Isolation and characterization of a novel human intestinal
Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The gut-liver/bile axis: Gut microbiota and bacterial extracellular vesicles remodeling hepatobiliary pathogenesis.iScience · 2026Review
- Metagenomic insights into urolithin formation from rambutan rind extract by rat faecal-derived microbiome.Applied microbiology and biotechnology · 2026Article
- Urolithin A: a multi-target therapeutic candidate derived from the gut microbiota for obesity and metabolic dysfunction.Frontiers in endocrinology · 2026Review
- The presence and induction of regioselective dehydroxylases dictate urolithin metabolism by Enterocloster species.NPJ biofilms and microbiomes · 2025Article
- Ellagic Acid and Gut Microbiota: Interactions, and Implications for Health.Food science & nutrition · 2025Review
- Diet-derived urolithin A is produced by a dehydroxylase encoded by human gut Enterocloster species.Nature communications · 2025Article
- In vitro conversion of ellagic acid to urolithin A by different gut microbiota of urolithin metabotype A.Applied microbiology and biotechnology · 2024Article
- Pharmacological Effects of Urolithin A and Its Role in Muscle Health and Performance: Current Knowledge and Prospects.Nutrients · 2023Review
- A Review of Gut Microbiota-Derived Metabolites in Tumor Progression and Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Genetic and Probiotic Characteristics of Urolithin A ProducingFoods (Basel, Switzerland) · 2023Article
- Effect of urolithin A on the improvement of vascular endothelial function depends on the gut microbiota.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urolithin A (UA) has received considerable research attention because of its health benefits. However, only a few strains have been reported to produce UA from ellagic acid (EA), and the molecular mechanisms underlying the gut microbiota-mediated transformation of ellagic acid into urolithin A is limited. In the present study, a single strain FUA027 capable of converting ellagic acid into UA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.